[Prevention of recurrence in urinary bladder tumors by intravesical instillation treatment with adriamycin].
109 patients with urinary bladder cancer received post TUR treatment with weekly intravesical instillations of Adriamycin for a period of 6 weeks. 32 patients received a dosage of 10 mg/50 ml physiological NaCl, 35 patients a dosage of 30 mg/50 ml physiological NaCl. We determined the oncolytical value and the value of prophylactically reduced recurrence through urine cytology and endoscopic controls with biopsies. After an observation period of 1 year the result was the same in all groups; 13% had a persistent tumour, 71% remained recurrence free. By raising the dosage of Adriamycin we achieved a reduction in the persister rate from 31% with 10 mg/50 ml NaCl to 6% with 30 mg/50 ml NaCl and to 5% with 50 mg/50 ml NaCl. There was no significant correlation between dosage and recurrence rate. The recurrence rate after a dosage of 10 mg/50 ml was 31%, after 30 mg/50 ml 73% and after 50 mg/50 ml 33%. The increasing recurrence rate correlates with the intensity of local tumour infiltration and with the grading of the primary tumours.
D000287:Administration, Topical; D000328:Adult; D000368:Aged; D002295:Carcinoma, Transitional Cell / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D003131:Combined Modality Therapy; D004305:Dose-Response Relationship, Drug; D004317:Doxorubicin / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000517:prevention & control*; D009367:Neoplasm Staging; D011379:Prognosis; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery
D004317:Doxorubicin
Rezidivprophylaxe bei Harnblasentumoren durch intravesikale Instillationsbehandlung mit Adriamycin.